(Q38143159)

29 August 2017

title

Safety profile of the yellow fever vaccine Stamaril®: a 17-year review (English)

1 reference

29 August 2017

0 references

1 reference

1 reference

2

Matthias Niedrig

1 reference

29 August 2017

Pascale Cottin

1

1 reference

29 August 2017

Cristina Domingo

series ordinal

3

1 reference

29 August 2017

publication date

25 September 2013

1 reference

Expert Review of Vaccines

29 August 2017

published in

1 reference

29 August 2017

volume

12

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

1351-1368

1 reference

The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Comparison of neurovirulence of different strains of yellow fever virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Combined vaccination against yellow fever and typhoid fever: a comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Yellow fever vaccination and pregnancy: a four-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Evaluation of two yellow fever vaccines for routine immunization programs in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Rarity of adverse effects after 17D yellow-fever vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Effects of yellow fever vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Yellow fever-associated viscerotropic disease in Barcelona, Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Acute viscerotropic disease following vaccination against yellow fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Short report: Incidence of yellow fever vaccine-associated neurotropic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Maternal age and fetal loss: population based register linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Adverse event reports following yellow fever vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

History of thymoma and yellow fever vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Yellow fever virus vaccine-associated deaths in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Review of the risks and benefits of yellow fever vaccination including some new analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

TLR expression and NK cell activation after human yellow fever vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Early exposure to yellow fever vaccine during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Congenital yellow fever virus infection after immunization in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Exposure to yellow fever vaccine in early pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons--Liberia, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Postvaccinal inflammatory neuropathy: peripheral nerve biopsy in 3 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

Yellow Fever Vaccine Post-marketing Surveillance in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.836320

10.1586/14760584.2013.836320

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference